JP2013531655A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531655A5
JP2013531655A5 JP2013514691A JP2013514691A JP2013531655A5 JP 2013531655 A5 JP2013531655 A5 JP 2013531655A5 JP 2013514691 A JP2013514691 A JP 2013514691A JP 2013514691 A JP2013514691 A JP 2013514691A JP 2013531655 A5 JP2013531655 A5 JP 2013531655A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
hybridoma
seq
produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013514691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531655A (ja
JP6081911B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/059868 external-priority patent/WO2011157724A1/en
Publication of JP2013531655A publication Critical patent/JP2013531655A/ja
Publication of JP2013531655A5 publication Critical patent/JP2013531655A5/ja
Application granted granted Critical
Publication of JP6081911B2 publication Critical patent/JP6081911B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013514691A 2010-06-14 2011-06-14 S100a4抗体およびその治療上の使用 Expired - Fee Related JP6081911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382170.8 2010-06-14
EP10382170 2010-06-14
PCT/EP2011/059868 WO2011157724A1 (en) 2010-06-14 2011-06-14 S100a4 antibodies and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017007296A Division JP6564408B2 (ja) 2010-06-14 2017-01-19 S100a4抗体およびその治療上の使用

Publications (3)

Publication Number Publication Date
JP2013531655A JP2013531655A (ja) 2013-08-08
JP2013531655A5 true JP2013531655A5 (cg-RX-API-DMAC7.html) 2014-07-31
JP6081911B2 JP6081911B2 (ja) 2017-02-15

Family

ID=43617041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013514691A Expired - Fee Related JP6081911B2 (ja) 2010-06-14 2011-06-14 S100a4抗体およびその治療上の使用
JP2017007296A Expired - Fee Related JP6564408B2 (ja) 2010-06-14 2017-01-19 S100a4抗体およびその治療上の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017007296A Expired - Fee Related JP6564408B2 (ja) 2010-06-14 2017-01-19 S100a4抗体およびその治療上の使用

Country Status (22)

Country Link
US (2) US8916152B2 (cg-RX-API-DMAC7.html)
EP (1) EP2580240B1 (cg-RX-API-DMAC7.html)
JP (2) JP6081911B2 (cg-RX-API-DMAC7.html)
KR (1) KR101869413B1 (cg-RX-API-DMAC7.html)
CN (1) CN103201290B (cg-RX-API-DMAC7.html)
AU (3) AU2011267089B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012032008B1 (cg-RX-API-DMAC7.html)
CA (1) CA2802631C (cg-RX-API-DMAC7.html)
CL (1) CL2012003538A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121742T1 (cg-RX-API-DMAC7.html)
DK (1) DK2580240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2717908T3 (cg-RX-API-DMAC7.html)
IL (1) IL223667B (cg-RX-API-DMAC7.html)
LT (1) LT2580240T (cg-RX-API-DMAC7.html)
MX (1) MX347734B (cg-RX-API-DMAC7.html)
NZ (1) NZ604643A (cg-RX-API-DMAC7.html)
PL (1) PL2580240T3 (cg-RX-API-DMAC7.html)
PT (1) PT2580240T (cg-RX-API-DMAC7.html)
RU (1) RU2615684C2 (cg-RX-API-DMAC7.html)
SM (1) SMT201900219T1 (cg-RX-API-DMAC7.html)
TR (1) TR201903026T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011157724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2615684C2 (ru) * 2010-06-14 2017-04-06 Ликера Биомед Са Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
RU2484096C1 (ru) * 2012-02-08 2013-06-10 Общество с ограниченной ответственностью "Технофарма" ОДНОДОМЕННОЕ АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ БЕЛОК S100A4/Mts1, ПРИМЕНЕНИЕ ПОЛУЧЕННОГО АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ ЭТОГО БЕЛКА
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
WO2014073653A1 (ja) * 2012-11-09 2014-05-15 国立大学法人福井大学 腎炎の病変部位の検査方法およびそのための試薬
JP2014094919A (ja) * 2012-11-09 2014-05-22 Univ Of Fukui 腎炎の予防または治療剤
SMT201700402T1 (it) 2013-04-09 2017-11-15 Lykera Biomed S A Anticorpi anti-s-100a7 per il trattamento e la diagnosi del cancro
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
CN112083167B (zh) * 2019-06-14 2024-03-26 复旦大学附属华山医院 S100a4作为评估甲氨蝶呤干预银屑病的生物标记物及其用途
WO2021011608A1 (en) * 2019-07-15 2021-01-21 University Of Connecticut Metallothionein antibodies and their use
KR102151133B1 (ko) * 2019-12-27 2020-09-02 주식회사 인투앱 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN115867355A (zh) * 2020-06-30 2023-03-28 艾瑞克斯疗法有限公司 用于治疗系统性硬化病的抗s100a4抗体
IL304971A (en) * 2021-02-09 2023-10-01 Arxx Therapeutics As Humanized anti-S100A4 antibody, uses and methods
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US6638504B1 (en) * 1990-07-09 2003-10-28 Research Corporation Technologies, Inc. Methods for treating cancer
JP3398149B2 (ja) * 1990-07-09 2003-04-21 リサーチ コーポレーション テクノロジーズ インコーポレーテッド Mts―1遺伝子による転移性の癌の診断
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
CA2371046A1 (en) * 1999-04-23 2000-11-02 Eugene Lukanidin Therapeutic compositions and methods for enhancing angiogenesis
DE10017249A1 (de) 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
EP1455813B1 (en) 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
EP1466016A2 (en) 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Cancer profiles
JP2004198419A (ja) 2002-12-13 2004-07-15 Bayer Healthcare Llc Timp1を用いた検出方法
US20050208518A1 (en) 2003-05-16 2005-09-22 Longueville Francoise D Method and apparatus for determination of RNAi cell transfection effects by multiple gene expression analysis on micro-arrays
US20040229225A1 (en) 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
EP1644519B1 (en) 2003-07-04 2008-12-31 Johnson & Johnson Research Pty Limited Method for detection of alkylated cytosine in dna
CA2534456A1 (en) 2003-08-01 2005-02-10 The University Of Western Australia Methods and kits for predicting the likelihood of successful treatment of cancer
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2006052795A2 (en) 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
KR100664589B1 (ko) 2004-12-28 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 및이를 포함하는 발현 벡터
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20060269948A1 (en) 2005-05-16 2006-11-30 Halloran Philip F Tissue rejection
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2121740A2 (en) * 2005-12-20 2009-11-25 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
US7972785B2 (en) 2006-01-24 2011-07-05 Industrial Technology Research Institute (Itri) Biomarkers for liver fibrotic injury
JP2007263896A (ja) 2006-03-29 2007-10-11 Univ Nagoya 肺癌患者の術後予後予測のための生物マーカー及びその方法
JP5420396B2 (ja) 2006-04-28 2014-02-19 シンガポール ヘルス サービシーズ ピーティーイー リミテッド 粘膜乾燥状態に関する検討
WO2008030278A2 (en) 2006-06-05 2008-03-13 Fred Hutchinson Cancer Research Center Assays for radiation exposure
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008037432A2 (en) 2006-09-27 2008-04-03 Charité - Universitätsmedizin Berlin METHODS FOR DIAGNOSING METASTASIS BY ANALYZING MUTATIONS IN β-CATENIN
EP2092075A2 (en) 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
EP2087140A2 (en) 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
DE102006056784A1 (de) 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
US20080234138A1 (en) 2006-12-08 2008-09-25 Shaughnessy John D TP53 gene expression and uses thereof
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US20080161203A1 (en) 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
US20100120788A1 (en) 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
AU2007350331A1 (en) 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20100216137A1 (en) 2007-04-05 2010-08-26 SOURCE PRECISION MEDICINE, INC d/b/a SOURCE MDX Gene Expression Profiling for Identification, Monitoring and Treatment of Ovarian Cancer
US20100330558A1 (en) 2007-04-06 2010-12-30 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Cervical Cancer
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US20090093005A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
RU2615684C2 (ru) * 2010-06-14 2017-04-06 Ликера Биомед Са Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии

Similar Documents

Publication Publication Date Title
JP2013531655A5 (cg-RX-API-DMAC7.html)
RU2013101529A (ru) Специфическое антитело к s100a4 или его фрагмент, способ их получения, фармацевтическая композиция их содержащая, гибридомная клеточная линия, конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, способ детекции s100a4, способ создания индивидуальной терапии
DK2493503T3 (en) DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody
US9945870B2 (en) Methods for determining responsiveness to an anti-CD47 agent
RU2015147287A (ru) Гуманизированные антитела против axl
JP2016520520A5 (cg-RX-API-DMAC7.html)
JP2012526530A5 (cg-RX-API-DMAC7.html)
JP2012012402A5 (cg-RX-API-DMAC7.html)
JP2017532005A5 (cg-RX-API-DMAC7.html)
RU2017107773A (ru) Антитела, специфичные к ммр9
US12222356B2 (en) Cytokine profiling analysis
JP2011518773A5 (cg-RX-API-DMAC7.html)
WO2015038538A1 (en) Compositions and methods for treating sepsis
WO2022082073A2 (en) Compositions and methods for muc18 targeting
HUE030578T2 (en) Use of Human Leukemia Inhibitor Antibody (LIF) and Antibodies to LIF to Treat Diseases Related to Unwanted Cell Proliferation
RU2016144178A (ru) Антитело против muc1 или его антигенсвязывающий фрагмент и его применение
TWI710575B (zh) 人類抗-fgfr4抗體
JP2009529497A5 (cg-RX-API-DMAC7.html)
JP2016509585A5 (cg-RX-API-DMAC7.html)
US20150361504A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
JP2017538439A5 (cg-RX-API-DMAC7.html)
EP2523687A1 (en) Methods for diagnosis and treatment of cutaneous t cell lymphomas
RU2014120577A (ru) Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний
Xia et al. Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma
JP2018532699A5 (cg-RX-API-DMAC7.html)